Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

Name: Work Video:
Duration: 3 min 30 s
Peter Schmid; Peter Savas; Enrique Espinosa; Valentina Boni; Antoîne Italiano; Shane White; Karen Cheng; Lisa H. Lam; Lídia Robert; Victor Laliman; Kalpit Shah; Marie‐Paule Sablin
{'id': 'https://openalex.org/W3132547876', 'doi': 'https://doi.org/10.1158/1538-7445.sabcs20-ps12-28', 'title': 'Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)', 'display_name': 'Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)', 'publication_year': 2021, 'publication_date': '2021-02-15', 'ids': {'openalex': 'https://openalex.org/W3132547876', 'doi': 'https://doi.org/10.1158/1538-7445.sabcs20-ps12-28', 'mag': '3132547876'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.sabcs20-ps12-28', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5111951182', 'display_name': 'Peter Schmid', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I166337079', 'display_name': 'Queen Mary University of London', 'ror': 'https://ror.org/026zzn846', 'country_code': 'GB', 'type': 'education', 'lineage': ['https://openalex.org/I124357947', 'https://openalex.org/I166337079']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'Peter Schmid', 'raw_affiliation_strings': ['1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom'], 'affiliations': [{'raw_affiliation_string': '1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom', 'institution_ids': ['https://openalex.org/I166337079']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5089161106', 'display_name': 'Peter Savas', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2800555584', 'display_name': 'Peter MacCallum Cancer Centre', 'ror': 'https://ror.org/02a8bt934', 'country_code': 'AU', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2800555584']}], 'countries': ['AU'], 'is_corresponding': False, 'raw_author_name': 'Peter Savas', 'raw_affiliation_strings': ['2Peter MacCallum Cancer Centre, Melbourne, Australia'], 'affiliations': [{'raw_affiliation_string': '2Peter MacCallum Cancer Centre, Melbourne, Australia', 'institution_ids': ['https://openalex.org/I2800555584']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5053108880', 'display_name': 'Enrique Espinosa', 'orcid': 'https://orcid.org/0000-0001-6562-7902'}, 'institutions': [{'id': 'https://openalex.org/I2800562746', 'display_name': 'Hospital Universitario La Paz', 'ror': 'https://ror.org/01s1q0w69', 'country_code': 'ES', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2800562746']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Enrique Espinosa', 'raw_affiliation_strings': ['3Hospital Universitario La Paz, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': '3Hospital Universitario La Paz, Madrid, Spain', 'institution_ids': ['https://openalex.org/I2800562746']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5020352800', 'display_name': 'Valentina Boni', 'orcid': 'https://orcid.org/0000-0002-8675-0018'}, 'institutions': [{'id': 'https://openalex.org/I4210117526', 'display_name': 'Unidades Centrales Científico-Técnicas', 'ror': 'https://ror.org/01wdt4y78', 'country_code': 'ES', 'type': 'facility', 'lineage': ['https://openalex.org/I2801357902', 'https://openalex.org/I4210117526', 'https://openalex.org/I4387152914']}], 'countries': ['ES'], 'is_corresponding': False, 'raw_author_name': 'Valentina Boni', 'raw_affiliation_strings': ['4START Madrid CIOCC, Madrid, Spain'], 'affiliations': [{'raw_affiliation_string': '4START Madrid CIOCC, Madrid, Spain', 'institution_ids': ['https://openalex.org/I4210117526']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5060949051', 'display_name': 'Antoîne Italiano', 'orcid': 'https://orcid.org/0000-0002-8540-5351'}, 'institutions': [{'id': 'https://openalex.org/I4210134409', 'display_name': 'Institut Bergonié', 'ror': 'https://ror.org/02yw1f353', 'country_code': 'FR', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210134409']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Antoine Italiano', 'raw_affiliation_strings': ['5Institut Bergonié, Bordeaux, France'], 'affiliations': [{'raw_affiliation_string': '5Institut Bergonié, Bordeaux, France', 'institution_ids': ['https://openalex.org/I4210134409']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5102993560', 'display_name': 'Shane White', 'orcid': 'https://orcid.org/0009-0003-6030-2801'}, 'institutions': [{'id': 'https://openalex.org/I4210109437', 'display_name': 'Footscray Hospital', 'ror': 'https://ror.org/0221nva21', 'country_code': 'AU', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210109437', 'https://openalex.org/I4210116486']}, {'id': 'https://openalex.org/I2800453128', 'display_name': 'Austin Hospital', 'ror': 'https://ror.org/010mv7n52', 'country_code': 'AU', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2800453128', 'https://openalex.org/I4210163497']}], 'countries': ['AU'], 'is_corresponding': False, 'raw_author_name': 'Shane White', 'raw_affiliation_strings': ['6Austin Hospital, Melbourne, Australia'], 'affiliations': [{'raw_affiliation_string': '6Austin Hospital, Melbourne, Australia', 'institution_ids': ['https://openalex.org/I4210109437', 'https://openalex.org/I2800453128']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5007993892', 'display_name': 'Karen Cheng', 'orcid': 'https://orcid.org/0000-0002-4004-4847'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Karen Cheng', 'raw_affiliation_strings': ['7Genentech, Inc., South San Francisco, CA;'], 'affiliations': [{'raw_affiliation_string': '7Genentech, Inc., South San Francisco, CA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5081721294', 'display_name': 'Lisa H. Lam', 'orcid': 'https://orcid.org/0000-0001-5188-9522'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Lisa Lam', 'raw_affiliation_strings': ['7Genentech, Inc., South San Francisco, CA;'], 'affiliations': [{'raw_affiliation_string': '7Genentech, Inc., South San Francisco, CA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5113880034', 'display_name': 'Lídia Robert', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Lidia Robert', 'raw_affiliation_strings': ['7Genentech, Inc., South San Francisco, CA;'], 'affiliations': [{'raw_affiliation_string': '7Genentech, Inc., South San Francisco, CA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5019614118', 'display_name': 'Victor Laliman', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210089084', 'display_name': 'Roche (Canada)', 'ror': 'https://ror.org/006hrz834', 'country_code': 'CA', 'type': 'company', 'lineage': ['https://openalex.org/I118019719', 'https://openalex.org/I4210089084']}], 'countries': ['CA'], 'is_corresponding': False, 'raw_author_name': 'Victor Laliman', 'raw_affiliation_strings': ['8Hoffmann-La Roche Limited, Mississauga, ON, Canada'], 'affiliations': [{'raw_affiliation_string': '8Hoffmann-La Roche Limited, Mississauga, ON, Canada', 'institution_ids': ['https://openalex.org/I4210089084']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5067655650', 'display_name': 'Kalpit Shah', 'orcid': 'https://orcid.org/0000-0001-6383-4625'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Kalpit Shah', 'raw_affiliation_strings': ['7Genentech, Inc., South San Francisco, CA;'], 'affiliations': [{'raw_affiliation_string': '7Genentech, Inc., South San Francisco, CA;', 'institution_ids': []}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5043109982', 'display_name': 'Marie‐Paule Sablin', 'orcid': 'https://orcid.org/0000-0003-4345-1576'}, 'institutions': [{'id': 'https://openalex.org/I80043', 'display_name': 'Institut Curie', 'ror': 'https://ror.org/04t0gwh46', 'country_code': 'FR', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I80043']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Marie-Paule Sablin', 'raw_affiliation_strings': ['9Institut Curie, Paris, France'], 'affiliations': [{'raw_affiliation_string': '9Institut Curie, Paris, France', 'institution_ids': ['https://openalex.org/I80043']}]}], 'institution_assertions': [], 'countries_distinct_count': 5, 'institutions_distinct_count': 9, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 1.877, 'has_fulltext': False, 'cited_by_count': 11, 'citation_normalized_percentile': {'value': 0.999974, 'is_in_top_1_percent': True, 'is_in_top_10_percent': True}, 'cited_by_percentile_year': {'min': 88, 'max': 89}, 'biblio': {'volume': '81', 'issue': '4_Supplement', 'first_page': 'PS12', 'last_page': '28'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T12829', 'display_name': 'Advanced Breast Cancer Therapies', 'score': 0.9974, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T12829', 'display_name': 'Advanced Breast Cancer Therapies', 'score': 0.9974, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11752', 'display_name': 'Cancer Treatment and Pharmacology', 'score': 0.9972, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9959, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/atezolizumab', 'display_name': 'Atezolizumab', 'score': 0.9271903}, {'id': 'https://openalex.org/keywords/taxane', 'display_name': 'Taxane', 'score': 0.8650029}, {'id': 'https://openalex.org/keywords/triple-negative-breast-cancer', 'display_name': 'Triple-negative breast cancer', 'score': 0.63606393}, {'id': 'https://openalex.org/keywords/progression-free-survival', 'display_name': 'Progression-free survival', 'score': 0.42520964}], 'concepts': [{'id': 'https://openalex.org/C2775949291', 'wikidata': 'https://www.wikidata.org/wiki/Q20707748', 'display_name': 'Atezolizumab', 'level': 5, 'score': 0.9271903}, {'id': 'https://openalex.org/C2777511904', 'wikidata': 'https://www.wikidata.org/wiki/Q425227', 'display_name': 'Taxane', 'level': 4, 'score': 0.8650029}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.84862435}, {'id': 'https://openalex.org/C2780110267', 'wikidata': 'https://www.wikidata.org/wiki/Q7843332', 'display_name': 'Triple-negative breast cancer', 'level': 4, 'score': 0.63606393}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.60914505}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.60538834}, {'id': 'https://openalex.org/C2775930923', 'wikidata': 'https://www.wikidata.org/wiki/Q12859063', 'display_name': 'Metastatic breast cancer', 'level': 4, 'score': 0.55372965}, {'id': 'https://openalex.org/C31760486', 'wikidata': 'https://www.wikidata.org/wiki/Q7180990', 'display_name': 'Phases of clinical research', 'level': 3, 'score': 0.49202535}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.4893548}, {'id': 'https://openalex.org/C2908647359', 'wikidata': 'https://www.wikidata.org/wiki/Q2625603', 'display_name': 'Population', 'level': 2, 'score': 0.48125646}, {'id': 'https://openalex.org/C530470458', 'wikidata': 'https://www.wikidata.org/wiki/Q128581', 'display_name': 'Breast cancer', 'level': 3, 'score': 0.44883674}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.44190043}, {'id': 'https://openalex.org/C2779984678', 'wikidata': 'https://www.wikidata.org/wiki/Q2145898', 'display_name': 'Response Evaluation Criteria in Solid Tumors', 'level': 4, 'score': 0.43141553}, {'id': 'https://openalex.org/C2780739268', 'wikidata': 'https://www.wikidata.org/wiki/Q2112244', 'display_name': 'Progression-free survival', 'level': 3, 'score': 0.42520964}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.19580767}, {'id': 'https://openalex.org/C2780057760', 'wikidata': 'https://www.wikidata.org/wiki/Q13896859', 'display_name': 'Pembrolizumab', 'level': 4, 'score': 0.12360647}, {'id': 'https://openalex.org/C99454951', 'wikidata': 'https://www.wikidata.org/wiki/Q932068', 'display_name': 'Environmental health', 'level': 1, 'score': 0.0}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.sabcs20-ps12-28', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.85, 'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4311332848', 'https://openalex.org/W4250466167', 'https://openalex.org/W4245186715', 'https://openalex.org/W4229066420', 'https://openalex.org/W4221038606', 'https://openalex.org/W3132547876', 'https://openalex.org/W3130663466', 'https://openalex.org/W3010740851', 'https://openalex.org/W2937318637', 'https://openalex.org/W2331329572'], 'abstract_inverted_index': {'Abstract': [0], 'Background:': [1], 'The': [2, 22], 'combination': [3, 56, 158, 293, 565], 'of': [4, 24, 57, 73, 185, 244, 278, 291, 303, 315, 334, 338, 362, 402, 501, 566, 586], 'immune': [5, 496], 'checkpoint': [6], 'modulators': [7], 'with': [8, 13, 133, 159, 205, 298], 'chemotherapy': [9, 14, 62, 118, 124], 'improves': [10], 'efficacy': [11, 30], 'compared': [12], 'alone': [15], 'in': [16, 31, 36, 67, 157, 287, 313, 328, 336, 342, 358, 499], 'PD-L1+': [17, 493], 'advanced': [18, 37, 114], 'TNBC': [19, 38], '(IMpassion130;': [20], 'KEYNOTE-355).': [21], 'addition': [23], 'IPAT': [25, 141, 215, 335], 'to': [26, 295, 332, 370], 'paclitaxel': [27], '(PAC)': [28, 445, 457], 'improved': [29], 'a': [32, 47, 54, 68, 201, 354, 405, 563, 571], 'phase': [33, 49], '2': [34], 'trial': [35], '(LOTUS).': [39], 'Preliminary': [40], 'overall': [41], 'response': [42, 245], 'rate': [43], '(ORR)': [44], 'data': [45, 253], 'from': [46, 88, 261], 'multicenter': [48], '1b': [50, 560], 'study': [51, 561], '(NCT03800836)': [52], 'evaluating': [53, 562], 'triplet': [55, 564], 'IPAT,': [58], 'atezolizumab,': [59, 569], 'and': [60, 92, 106, 147, 195, 248, 322, 325, 340, 397, 570], 'taxane': [61, 377, 572], 'showed': [63], 'promising': [64], 'anti-tumor': [65], 'activity': [66], 'similar': [69], 'patient': [70], 'population,': [71], 'irrespective': [72], 'PD-L1': [74, 371], 'status': [75, 104, 375], '[Schmid,': [76], 'AACR': [77], '2019].': [78], 'Here,': [79], 'we': [80], 'report': [81, 361], 'follow-up': [82, 279], 'results': [83, 258, 284, 352], 'including': [84], 'progression-free': [85], 'survival': [86], '(PFS)': [87], 'this': [89], 'study.': [90], 'Patients': [91, 132, 138], 'Methods:': [93], 'Eligible': [94], 'patients': [95, 263, 316, 339, 403, 421], 'had': [96, 107], 'measurable': [97], 'unresectable': [98], 'locally': [99, 577], 'advanced/metastatic': [100, 578], 'TNBC,': [101], 'ECOG': [102], 'performance': [103], '0/1,': [105], 'received': [108, 139], 'no': [109, 380], 'prior': [110], 'systemic': [111], 'therapy': [112, 204, 575], 'for': [113, 576], 'disease': [115], '(prior': [116], '[neo]adjuvant': [117], 'and/or': [119], 'radiation': [120], 'permitted': [121], 'if': [122], 'all': [123], 'was': [125, 280], 'completed': [126], '≥12': [127], 'months': [128, 414, 418], 'before': [129], 'first': [130, 364], 'dose).': [131], 'brain': [134], 'metastases': [135], 'were': [136, 178, 230, 237, 259, 348], 'excluded.': [137], 'oral': [140], '400': [142], 'mg/day': [143], 'on': [144, 152, 171, 210, 395], 'days': [145, 153, 172, 182], '1–21': [146], 'IV': [148], 'atezolizumab': [149, 223, 341], '840': [150], 'mg': [151], '1': [154], '&amp;': [155, 175], '15': [156, 212], 'PAC': [160], '80': [161], 'mg/m2': [162, 168], '(Arm': [163, 169, 213, 264], 'A)': [164], 'or': [165, 190, 372, 376, 517], 'nab-PAC': [166], '100': [167], 'B)': [170], '1,': [173], '8,': [174], '15.': [176], 'Cycles': [177], 'repeated': [179], 'every': [180, 232], '28': [181], 'until': [183], 'loss': [184], 'clinical': [186], 'benefit,': [187], 'unacceptable': [188], 'toxicity,': [189], 'consent': [191], 'withdrawal.': [192], 'Arms': [193], 'C': [194, 271], 'D': [196, 274], 'evaluated': [197], 'sequential': [198], 'regimens': [199], 'comprising': [200], 'doublet': [202], 'induction': [203], 'the': [206, 252, 288, 292, 299, 304, 359, 363, 502, 587], 'third': [207], 'agent': [208], 'added': [209], 'day': [211], 'C:': [214], '+': [216, 219, 224, 227], 'PAC,': [217, 225], 'then': [218, 226], 'atezolizumab;': [220], 'Arm': [221, 267, 270, 273], 'D:': [222], 'IPAT).': [228], 'Tumors': [229], 'assessed': [231], '8': [233], 'weeks.': [234], 'Key': [235], 'endpoints': [236], 'confirmed': [238], 'ORR': [239, 356], '(per': [240], 'RECIST': [241], 'v1.1),': [242], 'duration': [243, 277], '(DoR),': [246], 'PFS,': [247, 417], 'safety.': [249], 'Results:': [250], 'At': [251], 'cut-off': [254], '(26': [255], 'Jul': [256], '2020),': [257], 'available': [260], '114': [262], 'A': [265], 'n=70,': [266], 'B': [268], 'n=20,': [269], 'n=12,': [272], 'n=12).': [275], 'Median': [276], '11.1': [281], 'months.': [282], 'Efficacy': [283], 'are': [285], 'summarized': [286], 'table.': [289], 'Safety': [290], 'appeared': [294], 'be': [296], 'consistent': [297, 381], 'known': [300], 'safety': [301, 346], 'profile': [302], 'individual': [305], 'drugs.': [306], 'Grade': [307], '≥3': [308], 'adverse': [309], 'events': [310], '(AEs)': [311], 'occurred': [312], '55%': [314], '(including': [317], 'rash': [318], '[13%],': [319], 'diarrhea': [320], '[12%],': [321], 'neutropenia': [323], '[10%])': [324], 'serious': [326], 'AEs': [327, 330], '34%.': [329], 'led': [331], 'discontinuation': [333], '6%': [337], '4%.': [343], 'No': [344], 'new': [345], 'signals': [347], 'identified.': [349], 'Conclusions:': [350], 'Updated': [351], 'demonstrate': [353], 'lower': [355], 'than': [357], 'preliminary': [360], '26': [365], 'patients.': [366, 480], 'Subgroup': [367], 'analyses': [368, 393], 'according': [369], 'PIK3CA/AKT1/PTEN': [373], 'alteration': [374, 519], 'backbone': [378], 'show': [379], 'trend': [382], 'across': [383], 'endpoints,': [384], 'although': [385], 'small': [386], 'sample': [387], 'sizes': [388], 'limit': [389], 'interpretation.': [390], 'Further': [391], 'biomarker': [392], 'focusing': [394], 'subgroups': [396], 'biology': [398], 'may': [399], 'identify': [400], 'subsets': [401], 'deriving': [404], 'benefit.': [406], 'PopulationConfirmed': [407], 'ORR,': [408], 'n': [409], '(%)': [410], '[95%': [411], 'CI]Median': [412], 'DoR,': [413], '(95%': [415, 419], 'CI)aMedian': [416], 'CI)All': [420], '(n=114)61': [422], '(54)': [423], '[44–63]7.3': [424], '(5.6–7.8)7.2': [425], '(5.5–7.4)PD-L1': [426], 'statusbPositive': [427], '(n=51)32': [428], '(63)': [429], '[48–76]7.4': [430], '(5.0–12.9)7.3': [431], '(5.4–7.4)Negative': [432], '(n=45)20': [433], '(44)': [434], '[30–60]5.6': [435], '(3.7–7.4)7.2': [436], '(5.4–9.1)Unknown': [437], '(n=18)9': [438], '(50)': [439, 459], '[26–74]11.1': [440], '(5.8–NE)6.3': [441], '(4.9–11.0)Arm': [442], '(taxane': [443], 'backbone)A': [444], '(n=70)36': [446], '(51)': [447], '[39–64]7.4': [448], '(5.6–12.9)7.2': [449], '(5.3–7.4)B': [450], '(nab-PAC)': [451], '(n=20)13': [452], '(65)': [453], '[41–85]7.3': [454], '(3.9–7.4)6.6': [455], '(3.4–9.0)C+D': [456], '(n=12+12)12': [458], '[29–71]6.8': [460], '(3.9–14.7)7.5': [461], '(5.5–11.3)PIK3CA/AKT1/PTEN': [462], 'statuscAltered': [463], '(n=36)d19': [464], '(53)': [465], '[35–70]6.8': [466], '(3.9–7.6)7.4': [467], '(5.5–9.1)Non-altered': [468], '(n=45)28': [469], '(62)': [470], '[47–76]7.3': [471], '(5.5–9.4)6.6': [472], '(5.2–9.0)Unknown': [473], '(n=33)14': [474], '(42)': [475], '[25–61]10.2': [476], '(5.8–NE)6.0': [477], '(5.1–9.1)aIn': [478], 'responding': [479], 'bAssessed': [481], 'by': [482], 'VENTANA': [483], 'SP142': [484], 'immunohistochemistry': [485], 'assay': [486], '(Ventana': [487], 'Medical': [488], 'Systems,': [489], 'Tucson,': [490], 'AZ,': [491], 'USA);': [492], 'defined': [494], 'as': [495, 573], 'cell': [497], 'expression': [498], '≥1%': [500], 'tumor': [503], 'area.': [504], 'cAssessed': [505], 'using': [506], 'FoundationOne': [507], 'CDx': [508], '(Foundation': [509], 'Medicine,': [510], 'Cambridge,': [511], 'MA,': [512], 'USA).': [513], 'dPIK3CA/AKT': [514], 'mutation': [515], '(n=12)': [516], 'PTEN': [518], '(n=24).': [520], 'CI': [521], '=': [522, 526, 530], 'confidence': [523], 'interval;': [524], 'nab': [525], 'nanoparticle': [527], 'albumin-bound;': [528], 'NE': [529], 'not': [531], 'estimable.': [532], 'Citation': [533], 'Format:': [534], 'Peter': [535, 537], 'Schmid,': [536], 'Savas,': [538], 'Enrique': [539], 'Espinosa,': [540], 'Valentina': [541], 'Boni,': [542], 'Antoine': [543], 'Italiano,': [544], 'Shane': [545], 'White,': [546], 'Karen': [547], 'Cheng,': [548], 'Lisa': [549], 'Lam,': [550], 'Lidia': [551], 'Robert,': [552], 'Victor': [553], 'Laliman,': [554], 'Kalpit': [555], 'Shah,': [556], 'Marie-Paule': [557], 'Sablin.': [558], 'Phase': [559], 'ipatasertib': [567], '(IPAT),': [568], 'first-line': [574], 'triple-negative': [579], 'breast': [580], 'cancer': [581], '(TNBC)': [582], '[abstract].': [583], 'In:': [584], 'Proceedings': [585], '2020': [588, 595], 'San': [589, 598], 'Antonio': [590], 'Breast': [591], 'Cancer': [592, 604], 'Virtual': [593], 'Symposium;': [594], 'Dec': [596], '8-11;': [597], 'Antonio,': [599], 'TX.': [600], 'Philadelphia': [601], '(PA):': [602], 'AACR;': [603], 'Res': [605], '2021;81(4': [606], 'Suppl):Abstract': [607], 'nr': [608], 'PS12-28.': [609]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3132547876', 'counts_by_year': [{'year': 2024, 'cited_by_count': 1}, {'year': 2023, 'cited_by_count': 5}, {'year': 2022, 'cited_by_count': 3}, {'year': 2021, 'cited_by_count': 2}], 'updated_date': '2024-12-13T14:14:10.391779', 'created_date': '2021-03-01'}
Publication Information

Basic Information

Access and Citation

AI Researcher Chatbot

Primary Location

Authors

Topics

Keywords

Related Works
